clinical trial · NCT05246514
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
HER2-mutant Non-Small Cell Lung CancerTrastuzumab deruxtecan
brief summary
The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
started
Jul 13, 2022
primary completion
Nov 4, 2024
completion
Dec 31, 2026
last updated
Aug 18, 2026
official title
An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After at Least One-line of Treatment (DESTINY-Lung05)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol